Correlation Between Monte Rosa and Enanta Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Monte Rosa and Enanta Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Monte Rosa and Enanta Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Monte Rosa Therapeutics and Enanta Pharmaceuticals, you can compare the effects of market volatilities on Monte Rosa and Enanta Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Monte Rosa with a short position of Enanta Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Monte Rosa and Enanta Pharmaceuticals.

Diversification Opportunities for Monte Rosa and Enanta Pharmaceuticals

0.71

Correlation Coefficient

Monte Rosa  Enanta Pharmaceuticals

Poor diversification

The 3 months correlation between Monte and Enanta is 0.71. Overlapping area represents the amount of risk that can be diversified away by holding Monte Rosa Therapeutics and Enanta Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Enanta Pharmaceuticals and Monte Rosa is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Monte Rosa Therapeutics are associated (or correlated) with Enanta Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Enanta Pharmaceuticals has no effect on the direction of Monte Rosa i.e., Monte Rosa and Enanta Pharmaceuticals go up and down completely randomly.

Pair Corralation between Monte Rosa and Enanta Pharmaceuticals

Given the investment horizon of 90 days Monte Rosa Therapeutics is expected to under-perform the Enanta Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Monte Rosa Therapeutics is 1.35 times less risky than Enanta Pharmaceuticals. The stock trades about -0.19 of its potential returns per unit of risk. The Enanta Pharmaceuticals is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest  860.00  in Enanta Pharmaceuticals on November 28, 2024 and sell it today you would lose (11.00) from holding Enanta Pharmaceuticals or give up 1.28% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Monte Rosa Therapeutics  vs.  Enanta Pharmaceuticals

Monte Rosa Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Monte Rosa Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in March 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Enanta Pharmaceuticals

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Enanta Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady basic indicators, Enanta Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in March 2025.

Pair Trading with Monte Rosa and Enanta Pharmaceuticals

The main advantage of trading using opposite Monte Rosa and Enanta Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Monte Rosa position performs unexpectedly, Enanta Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enanta Pharmaceuticals will offset losses from the drop in Enanta Pharmaceuticals' long position.

The idea behind Monte Rosa Therapeutics and Enanta Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.